HPV antigens, vaccine compositions, and related methods

• US 20080279877A1
• Filed: 02/13/2007
• Published: 11/13/2008
• Est. Priority Date: 02/13/2006
• Status: Abandoned Application

• Current Assignee: Fraunhofer USA Inc. (Fraunhofer-Institut für Nachrichtentechnik HHI)
• Original Assignee: Fraunhofer USA Inc. (Fraunhofer-Institut für Nachrichtentechnik HHI)
• Inventors: Yusibov, Vidadi, Mett, Vadim
• Application Number:
  US11/706,568
• Publication Number:
  US 20080279877A1
• Time in Patent Office: Days
• US Class Current: 424/186.1
• CPC Class Codes: A61K 2039/55577 Saponins; Quil A; QS21; ISCOMS
• CPC Class Codes: A61K 2039/585 wherein the target is cancer
• CPC Class Codes: A61K 2039/6031 Proteins
• CPC Class Codes: A61K 39/00 Medicinal preparations containing antigens or antibodies materials for immunoassay G01N33/53
• CPC Class Codes: A61K 39/12 Viral antigens
• CPC Class Codes: A61P 31/12 Antivirals
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/00 Drugs for immunological or allergic disorders
• CPC Class Codes: C07K 14/005 from viruses
• CPC Class Codes: C07K 2319/35 containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
• CPC Class Codes: C12N 2710/20022 New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
• CPC Class Codes: C12N 2710/20034 Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
• CPC Class Codes: C12N 7/00 Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00
• CPC Class Codes: C12N 9/2448 Licheninase (3.2.1.73)
• CPC Class Codes: C12Y 302/01073 Licheninase (3.2.1.73)

Abstract

The present invention relates to the intersection of the fields of immunology and protein engineering, and particularly to antigens and vaccines useful in prevention of infection by human papilloma virus. Provided are recombinant protein antigens, compositions, and methods for the production and use of such antigens and vaccine compositions.

Claims

1. An isolated antigen comprising a component of human papilloma virus (HPV) fused to a thermostable protein;

wherein the HPV component comprises at least one domain selected from the group consisting of E7 from HPV16, E7 from HPV18, E6 from HPV16, and E6 from HPV18, a fragment of E7 from HPV16, a fragment of E7 from HPV18, a fragment of E6 from HPV16, and a fragment of E6 from HPV18.

2-10. -10. (canceled)

11. A vaccine composition comprising an antigen comprising a component of human papilloma virus (HPV) fused to a thermostable protein and a pharmaceutically acceptable carrier;

wherein the HPV component comprises at least one domain selected from the group consisting of E7 from HPV16, E7 from HPV18, E6 from HPV16, and E6 from HPV18, a fragment of E7 from HPV16, a fragment of E7 from HPV18, a fragment of E6 from HPV16, and a fragment of E6 from HPV18; and

wherein the composition is capable of eliciting an immune response upon administration to a subject.

21. (canceled)

28. A vaccine composition comprising at least two antigens, each of which comprises a component of human papilloma virus (HPV), wherein at least one of the antigens further comprises a thermostable protein, wherein the composition is capable of eliciting an immune response upon administration to an subject.

12. The vaccine composition of claim 28, wherein the HPV component consists of E7 from HPV16.

13. The vaccine composition of claim 28, wherein the HPV component consists of E7 from HPV18

14. The vaccine composition of claim 28, wherein the HPV component consists of SEQ ID NO.:

2 or SEQ ID NO.;

4.

15. The vaccine composition of claim 28, wherein the thermostable protein comprises a modified lichenase protein sequence.

16. The vaccine composition of claim 15, wherein the coding sequence for lichenase has been optimized for protein expression in plants.

17. The vaccine composition of claim 15, wherein the lichenase protein sequence comprises the N-terminal domain, the C-terminal domain, and the surface loop domain of lichenase.

18. The vaccine composition of claim 15, wherein the HPV component is fused to lichenase, and wherein the fusion is any one of an N-terminal fusion, a C-terminal fusion, or a surface loop insertion fusion protein.

19. The vaccine composition of claim 28, wherein the HPV component comprises at least two domains independently selected from the group consisting of E7 from HPV16, E7 from HPV18, E6 from HPV16, and E6 from HPV18, a fragment of E7 from HPV16, a fragment of E7 from HPV18, a fragment of E6 from HPV16, and a fragment of E6 from HPV18.

20. The vaccine composition of claim 19, wherein the first HPV component comprises E7 from HPV16 and the second HPV component comprises E7 from HPV18.

22. The vaccine composition of claim 28, wherein each of the at least two antigens comprises a component of human papilloma virus (HPV) fused to a thermostable protein and a pharmaceutically acceptable carrier;

wherein the HPV component of the first antigen comprises at least one domain selected from the group consisting of E7 from HPV16, E7 from HPV18, E6 from HPV16, and E6 from HPV18, a fragment of E7 from HPV16, a fragment of E7 from HPV18, a fragment of E6 from HPV16, and a fragment of E6 from HPV18, and the HPV component of the second antigen comprises at least one domain distinct from the first antigen selected from the group consisting of E7 from HPV16, E7 from HPV18, E6 from HPV16, and E6 from HPV18, a fragment of E7 from HPV16, a fragment of E7 from HPV18, a fragment of E6 from HPV16, and a fragment of E6 from HPV18; and

wherein the composition is capable of eliciting an immune response upon administration to an subject.

23. The vaccine composition of claim 22, wherein the HPV component of the first antigen comprises at least one domain selected from the group consisting of E7 from HPV16, and a fragment of E7 from HPV16, and the HPV component of the second antigen comprises at least one domain distinct from the first antigen selected from the group consisting of E7 from HPV18, and a fragment of E7 from HPV18.

24. The vaccine composition of claim 28 wherein at least one antigen is produced in a plant selected from a transgenic plant and a plant transiently expressing the antigen.

25. The vaccine composition of claim 28 wherein the composition comprises antigen which is purified, partially purified, or unpurified from plant cells, a plant, seeds, fruit, or an extract thereof.

26. The vaccine composition of claim 28, further comprising a vaccine adjuvant.

27. The vaccine composition of claim 28 wherein the adjuvant comprises alum, MF59, MALP2, and saponin.

29. The vaccine composition of claim 28, wherein each of the at least two antigens comprises a component of HPV each of which independently comprises at least one domain selected from the group consisting of E7 from HPV16, E7 from HPV18, E6 from HPV16, and E6 from HPV18, a fragment of E7 from HPV16, a fragment of E7 from HPV18, a fragment of E6 from HPV16, and a fragment of E6 from HPV18 and combinations thereof, and wherein the composition is capable of eliciting an immune response upon administration to an subject.

30. A method for inducing a protective immune response against human papilloma virus (HPV) infection in a subject comprising administering to a subject an effective amount of an anti-HPV vaccine composition, wherein the administration is sufficient to stimulate production of antigen specific antibodies or stimulate a cellular immune response by the subject;

thereby inducing a protective immune response;

a. wherein the vaccine composition comprises antigen comprising a component of human papilloma virus (HPV) fused to a thermostable protein; and

b. wherein the HPV component comprises at least one domain at least one domain selected from the group consisting of E7 from HPV16, E7 from HPV18, E6 from HPV16, and E6 from HPV18, a fragment of E7 from HPV16, a fragment of E7 from HPV18, a fragment of E6 from HPV16, and a fragment of E6 from HPV18.

31-33. -33. (canceled)

34. A method for producing an antigen protein comprising a component of human papilloma virus (HPV) fused to a thermostable protein, comprising:

a. preparing a nucleic acid construct encoding an antigen component of human papilloma virus (HPV) fused to a thermostable protein;

b. transforming a cell with the nucleic acid construct of step a; and

c. incubating the cell under conditions favorable for expression of the antigen protein;

d. thereby producing the antigen protein;

e. wherein the HPV component of the antigen comprises at least one domain selected from the group consisting of selected from the group consisting of E7 from HPV16, E7 from HPV18, E6 from HPV16, and E6 from HPV18, a fragment of E7 from HPV16, a fragment of E7 from HPV18, a fragment of E6 from HPV16, and a fragment of E6 from HPV18.

35-51. -51. (canceled)

52. An isolated nucleic acid construct comprising nucleic acid sequence encoding a component of human papilloma virus (HPV) fused to a thermostable protein;

wherein the HPV component comprises at least one domain selected from the group consisting of E7 from HPV16, E7 from HPV18, E6 from HPV16, and E6 from HPV18, a fragment of E7 from HPV16, a fragment of E7 from HPV18, a fragment of E6 from HPV16, and a fragment of E6 from HPV18 and combinations thereof.

66. A cell comprising the nucleic acid construct of claim 52.

69. A plant comprising the nucleic acid construct of claim 52, wherein the plant is capable of producing the antigen protein.

53-65. -65. (canceled)

67-68. -68. (canceled)

70-71. -71. (canceled)